GlassScriptPhysician profile
Jason L Hoke
NPI 1992969661
$4,806.02
in general payments reported to CMS, 2019-2025
36 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.13 · 2020: $405 · 2021: $730 · 2022: $661 · 2023: $985 · 2024: $942 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $866.18 | 2019-2025 | |
| Pfizer INC. | $744.98 | 2020-2025 | |
| Novo Nordisk INC | $455.80 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $445.96 | 2020-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $386.89 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $303.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $198.62 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.24 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.53 | 2020-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $117.06 | 2019-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $108.83 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.09 | 2021-2025 | |
| Abbott Laboratories | $94.14 | 2024-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $92.39 | 2020-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.32 | 2025 | Caplyta |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $56.11 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $37.59 | 2022 | |
| Merck Sharp & Dohme LLC | $36.86 | 2022-2025 | Capvaxive |
| Radius Health, INC. | $35.33 | 2019-2022 | |
| Astellas Pharma US INC | $28.48 | 2021-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $27.15 | 2022 | |
| Axsome Therapeutics, INC. | $23.88 | 2024 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $23.70 | 2021 | |
| Seqirus USA INC | $20.48 | 2024 | Flucelvax, Fluad |
| Sanofi Pasteur INC. | $19.25 | 2023 | |
| Vanda Pharmaceuticals INC. | $19.00 | 2025 | Fanapt |
| Halozyme INC | $18.91 | 2023 | |
| Antares Pharma, INC. | $18.01 | 2025 | Xyosted |
| Corcept Therapeutics | $17.05 | 2024 | Korlym |
| Averitas Pharma INC. | $17.01 | 2023 | Qutenza |
| Esperion Therapeutics, INC. | $16.31 | 2021 | |
| Grifols USA, LLC | $16.08 | 2021 | |
| Neos Therapeutics, LP | $14.92 | 2021 | |
| Exact Sciences Corporation | $13.71 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $12.67 | 2021 | |
| Allergan, INC. | $12.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Hoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.